Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189434 | 0.88 | LMNA (0.50) | LMNAPOLBHPGDGRM7PIK3CA | |
| SCHEMBL14510072 | 0.86 | KMT2A (0.51) | LMNAPOLBHPGDL3MBTL1MEN1 | |
| SCHEMBL14042690 | 0.82 | CA2 (0.54) | LMNANPC1RAB9ACTBP2MEN1 | |
| SCHEMBL10069933 | 0.81 | LMNA (0.39) | LMNAPOLBNPC1RAB9AL3MBTL1 | |
| SCHEMBL9664669 | 0.80 | GAA (0.47) | LMNAPOLBCTBP2MEN1KMT2A | |
| SCHEMBL12834066 | 0.80 | HPGD (0.50) | POLBHPGDNPC1RAB9ACTBP2 | |
| SCHEMBL9561721 | 0.80 | SIGMAR1 (0.68) | MAPTMEN1KMT2ASIGMAR1 | |
| SCHEMBL1155730 | 0.79 | FAAH (0.55) | LMNAHPGDL3MBTL1MAPTMEN1 | |
| SCHEMBL5646773 | 0.78 | ALDH1A1 (0.48) | POLBL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL14346117 | 0.76 | PPARG (0.52) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970391-B | Process for preparing pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN | 2013-09-18 | — | — | CN | disclosed |
| US-8394993-B2 | Process for the preparation of pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-03-12 | — | — | US | disclosed |
| EP-2231575-B1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2011-06-22 | — | — | EP | disclosed |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | PF4, F2, F3 | LMNA 3000/4885POLB 3123/4885HPGD 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.